Pretreatment disease characteristics
| . | ADE (n = 61) . | ADEP (n = 59) . | Total (n = 120) . |
|---|---|---|---|
| Type of AML | |||
| De novo | 45 (74%) | 43 (73%) | 88 (73%) |
| Prior MDS | 16 (26%) | 16 (27%) | 32 (27%) |
| Prior chemotherapy/radiation therapy (not for AML) | |||
| No prior MDS | 5 (8%) | 1 (2%) | 6 (5%) |
| Prior MDS | 2 (3%) | 2 (3%) | 4 (3%) |
| FAB type | |||
| M0 | 2 (3%) | 2 (3%) | 4 (3%) |
| M1 | 12 (20%) | 12 (20%) | 24 (20%) |
| M2 | 23 (38%) | 22 (37%) | 45 (38%) |
| M4 | 11 (18%) | 9 (15%) | 20 (17%) |
| M5 | 3 (5%) | 6 (10%) | 9 (8%) |
| M6 | 4 (7%) | 3 (5%) | 7 (6%) |
| M7 | 1 (2%) | 0 (0%) | 1 (1%) |
| AML, not specified | 2 (3%) | 2 (3%) | 4 (3%) |
| Other acute leukemia | 3 (5%) | 3 (5%) | 6 (5%) |
| Cytogenetic risk | |||
| Low | 3 (5%) | 3 (5%) | 6 (5%) |
| Intermediate | 29 (48%) | 30 (51%) | 59 (49%) |
| High | 7 (11%) | 8 (14%) | 15 (13%) |
| No risk assignment | 7 (11%) | 4 (7%) | 11 (9%) |
| Not evaluable | 7 (11%) | 6 (10%) | 13 (11%) |
| Not available | 8 (13%) | 8 (14%) | 16 (13%) |
| DiOC2(3) efflux ± PSC-8333-150 | |||
| Median | 0.29 | 0.25 | 0.26 |
| Range | 0.04-0.89 | 0.00-0.93 | 0.00-0.93 |
| D 0.2 or more | 22 (67%) | 21 (64%) | 43 (65%) |
| MRK16 staining3-150 | |||
| Median | 0.13 | 0.10 | 0.12 |
| Range | 0.02-0.69 | 0.03-0.53 | 0.02-0.69 |
| D 0.1 or more | 25 (76%) | 18 (55%) | 43 (65%) |
| . | ADE (n = 61) . | ADEP (n = 59) . | Total (n = 120) . |
|---|---|---|---|
| Type of AML | |||
| De novo | 45 (74%) | 43 (73%) | 88 (73%) |
| Prior MDS | 16 (26%) | 16 (27%) | 32 (27%) |
| Prior chemotherapy/radiation therapy (not for AML) | |||
| No prior MDS | 5 (8%) | 1 (2%) | 6 (5%) |
| Prior MDS | 2 (3%) | 2 (3%) | 4 (3%) |
| FAB type | |||
| M0 | 2 (3%) | 2 (3%) | 4 (3%) |
| M1 | 12 (20%) | 12 (20%) | 24 (20%) |
| M2 | 23 (38%) | 22 (37%) | 45 (38%) |
| M4 | 11 (18%) | 9 (15%) | 20 (17%) |
| M5 | 3 (5%) | 6 (10%) | 9 (8%) |
| M6 | 4 (7%) | 3 (5%) | 7 (6%) |
| M7 | 1 (2%) | 0 (0%) | 1 (1%) |
| AML, not specified | 2 (3%) | 2 (3%) | 4 (3%) |
| Other acute leukemia | 3 (5%) | 3 (5%) | 6 (5%) |
| Cytogenetic risk | |||
| Low | 3 (5%) | 3 (5%) | 6 (5%) |
| Intermediate | 29 (48%) | 30 (51%) | 59 (49%) |
| High | 7 (11%) | 8 (14%) | 15 (13%) |
| No risk assignment | 7 (11%) | 4 (7%) | 11 (9%) |
| Not evaluable | 7 (11%) | 6 (10%) | 13 (11%) |
| Not available | 8 (13%) | 8 (14%) | 16 (13%) |
| DiOC2(3) efflux ± PSC-8333-150 | |||
| Median | 0.29 | 0.25 | 0.26 |
| Range | 0.04-0.89 | 0.00-0.93 | 0.00-0.93 |
| D 0.2 or more | 22 (67%) | 21 (64%) | 43 (65%) |
| MRK16 staining3-150 | |||
| Median | 0.13 | 0.10 | 0.12 |
| Range | 0.02-0.69 | 0.03-0.53 | 0.02-0.69 |
| D 0.1 or more | 25 (76%) | 18 (55%) | 43 (65%) |
KS D value; n = 33 in each arm.